NCT01639625View on ClinicalTrials.gov

Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

September 30, 2015

Study Completion Date

January 31, 2016

Conditions
Squamous Cell Carcinoma of the CervixAdenocarcinoma of the Cervix
Interventions
DRUG

CIGB300

CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.

Trial Locations (1)

C1417DTB

Instituto de Oncologia Angel H. Roffo, Ciudad Autonoma de Buenos Aires

Sponsors
All Listed Sponsors
lead

Laboratorio Elea Phoenix S.A.

INDUSTRY